Free shipping on all orders over $ 500

LY2090314

Cat. No. M2826

All AbMole products are for research use only, cannot be used for human consumption.

LY2090314 Structure
Size Price Availability Quantity
1mg USD 50 In stock
5mg USD 105 In stock
10mg USD 165 In stock
50mg USD 480 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. Phase 1/2.

Customer Product Validations & Biological Datas
Source BMC Cancer (2018). Figure 2. LY2090314
Method MTT assay
Cell Lines SH-SY-5Y cells
Concentrations 10, 20, and 50 nM
Incubation Time 48, 72, and 96 h
Results In Fig. 1a, a steep reduction on average of 23% at 48 h, 42% at 72 h, and 61% at 96 h was noted in NGP cells treated with 20 nM of LY2090314.
Chemical Information
Molecular Weight 512.53
Formula C28H25FN6O3
CAS Number 603288-22-8
Solubility (25°C) DMSO 10 mM
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Alessio Reggio, et al. Adipogenesis of skeletal muscle fibro/adipogenic progenitors is affected by the WNT5a/GSK3/β-catenin axis

[2] Guoxu Fang, et al. Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling

[3] Selvi Kunnimalaiyaan, et al. Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro

[4] Jennifer M Atkinson, et al. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3

[5] Maciej J Zamek-Gliszczynski, et al. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure

Related GSK-3 Products
CHIR-99021

CHIR-99021 (CT99021) is an aminopyrimidine derivative that inhibits GSK3α and GSK3β with IC50 values of 10 and 6.7 nM, respectively.

CHIR-99021 HCl

CHIR-99021 HCl (Laduviglusib; CT99021) is a hydrochloride of CHIR-99021, with IC50 of 10 nM and 6.7 nM for GSK-3α and GSK-3β, respectively.

SB 216763

SB 216763 is a potent and selective, cell permeable glycogen synthase kinase-3 (GSK-3) inhibitor with an IC50 value of 34 nM for GSK-3α.

AZD2858

AZD2858 is a potent, orally bioactive inhibitor of GSK-3 with an IC50 of 68 nM.

Indirubin

Indirubin is a potent cyclin-dependent kinases and GSK-3β inhibitor with IC50 of ~75 nM and 0.19 μM.

  Catalog
Abmole Inhibitor Catalog




Keywords: LY2090314 supplier, GSK-3, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.